Castle Biosciences Inc., a Friendswood, Texas-based cancer-focused molecular diagnostics company, completed an $11.8m financing.
The round was led by new investor HealthQuest Capital, with participation from current investors Mountain Group Capital and Affiliates, Longfellow Venture Partners and others. In conjunction with this financing, Garheng Kong, M.D., Ph.D., Managing Partner of HealthQuest Capital, will join Castle Biosciences’ Board of Directors.
The company intends to use the funds to expand clinical availability of its portfolio of practice-changing cancer diagnostic tests, including DecisionDx-Melanoma, its test to determine metastatic risk in patients with melanoma.
Led by Derek Maetzold, President and CEO, Castle Biosciences is a molecular diagnostics and prognostics company that offers prognostic tests for patients with rare cancers including uveal and cutaneous melanoma, esophageal, thymoma and brain cancers as well as malignant pleural mesothelioma.
FinSMEs
14/08/2014